By Fineline Cube 
Mirxes Holding Company Limited (HKG: 2629) announced it has entered into a memorandum of understanding (MOU) with XtalPi Holdings Limited (HKG: 2228) to jointly build an AI-enabled integrated diagnosis and intervention platform for Asian high-incidence cancers, with initial focus on gastrointestinal (GI) cancers.
Partnership Framework & Strategic Focus
| Element | Details |
|---|---|
| Companies | Mirxes Holding (2629.HK) + XtalPi Holdings |
| Agreement Type | Memorandum of Understanding (MOU) |
| Term | 2 years from signing date |
| Technology Integration | Mirxes genomics + Asian disease database × XtalPi AI+ robotics drug discovery |
| Primary Focus | Early detection and intervention of GI cancers |
| Platform Model | “Integrated diagnosis and intervention” combining diagnosis and treatment |
Core Strengths & Synergies
Mirxes Contribution:
- Genomics Technology: Proprietary miRNA-based early cancer detection platforms
- Asian Disease Database: Vast repository of Asian population-specific cancer data
- Clinical Validation: Established networks for real-world evidence generation
XtalPi Contribution:
- AI+Robotics Platform: Leading drug discovery and research platform leveraging quantum physics, AI, and automation
- R&D Acceleration: Capable of reducing discovery timelines from years to months
- Molecule Design: Proprietary algorithms for novel therapeutic design
Combined Value:
- First-of-its-kind: Integrates upstream diagnostics with downstream therapeutic development
- Population-specific: Tailored for Asian cancer epidemiology (e.g., gastric, colorectal, liver cancers)
- End-to-end: From early screening to targeted intervention in single ecosystem
Market Context & Development Path
Asian GI Cancer Burden:
- Incidence: GI cancers account for >50% of cancer mortality in Asia
- Market Size: Asian cancer diagnostics market projected $15 billion by 2030; targeted therapeutics $25 billion
- Unmet Need: Limited early detection tools and targeted therapies specific to Asian populations
Platform Development:
- Phase 1 (2026): Integrate databases and validate AI prediction models
- Phase 2 (2027): Initiate co-development of diagnostic assays and companion therapeutics
- Phase 3 (2028): Launch clinical validation studies across multiple Asian countries
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the Mirxes-XtalPi partnership execution, platform development timelines, and commercial prospects. Actual results may differ due to technology integration challenges, regulatory processes, and competitive dynamics in AI-driven drug discovery.-Fineline Info & Tech